Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Allogeneic mesenchymal stem cell therapy combined with photobiomodulation for neonatal soft-tissue necrosis: A case report.

Rodrigues TAF., Dos Santos EV., de Figueiredo MJPSS., Scarcelli PG., Silva LP., das Neves SC.

Clinical Trial on Chronic Wound, published in Curr Res Transl Med (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Curr Res Transl Med (2026)
Country
France
Reported sample size
—
Source database
PubMed
PMID
42398474
DOI
10.1016/j.retram.2026.103599

Abstract (original English)

A 15-day-old neonate was admitted to a neonatal intensive care unit with peripheral ischemia and a right upper limb abscess following Bacillus Calmette-Guérin (BCG) vaccination. Laboratory findings revealed protein C and S deficiencies with elevated d-dimer levels. Imaging demonstrated a cerebral ischemic lesion secondary to coagulopathy, supporting a diagnosis of purpura fulminans. Initial management included abscess drainage followed by extensive surgical debridement of necrotic tissue, anticoagulation, and partial wound suturing. After the third debridement, the infant received four weekly infusions of 1 × 10 7 allogeneic adipose-derived mesenchymal stem cells, suspended in 2 mL of saline solution, and administered across 10-15 intralesional and perilesional injection sites. Daily photobiomodulation therapy was used as an adjunctive treatment for analgesia and tissue regeneration. Following the first cell therapy session, progressive reduction in lesion depth and enhanced vascularization were observed, culminating in complete wound closure 70 days after the initial cell therapy session. This approach may support future advances in cell therapy and regenerative medicine for the treatment of difficult-to-heal wounds in neonates and provides a rationale for prospective, randomized, controlled clinical trials.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research